RTW Investments, LP and its Managing Partner Roderick Wong, M.D. filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 8,535,153 shares of Pyxis Oncology, Inc. common stock as of September 30, 2026.
Highbridge Capital Management, LLC filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 8,738,712 shares of Class A Common Stock of Solana Company as of September 30, 2026.
Highbridge Capital Management, LLC filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 733,393 Class A Ordinary Shares of ARC Group Securities Acquisition I as of September 30, 2026.
Highbridge Capital Management, LLC filed an amended ownership statement with the SEC on November 16, 2026, disclosing that it no longer holds any beneficial ownership in the ordinary shares of Mountain Crest Acquisition 6 Corp.
RTW Investments, LP and Roderick Wong, M.D. filed Amendment No. 2 to a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 8,491,525 shares of Replimune Group, Inc. common stock as of September 30, 2026.
Highbridge Capital Management, LLC filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 1,257,485 Class A Ordinary Shares of BOA Acquisition Corp. II as of September 30, 2026.
Highbridge Capital Management, LLC filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 1,900,000 Class A Ordinary Shares of Cantor Equity Partners I, Inc. as of September 30, 2026.
Highbridge Capital Management, LLC filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 683,662 Class A Ordinary Shares of NMP Acquisition Corp., representing 5.6% of the class, as of a triggering event dated September 30, 2026.
Highbridge Capital Management, LLC filed an amended beneficial ownership statement with the SEC on November 16, 2026, disclosing an 8.1% stake in Nuburu, Inc. based on 819,821 shares of common stock issuable upon exercise of warrants held by Highbridge-managed funds.
Highbridge Capital Management, LLC filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 4,761,905 shares of Cardiff Oncology, Inc. common stock issuable upon exercise of warrants, representing 5.8% of the class as of September 30, 2026.